Display options
Cite
Masoud GN, Li W. HIF-1α pathway: role, regulation and intervention for cancer therapy. Acta Pharm Sin B. 2015;5(5):378-89doi: 10.1016/j.apsb.2015.05.007.
Masoud, G. N., & Li, W. (2015). HIF-1α pathway: role, regulation and intervention for cancer therapy. Acta pharmaceutica Sinica. B, 5(5), 378-89. https://doi.org/10.1016/j.apsb.2015.05.007
Masoud, Georgina N, and Li, Wei. "HIF-1α pathway: role, regulation and intervention for cancer therapy." Acta pharmaceutica Sinica. B vol. 5,5 (2015): 378-89. doi: https://doi.org/10.1016/j.apsb.2015.05.007
Masoud GN, Li W. HIF-1α pathway: role, regulation and intervention for cancer therapy. Acta Pharm Sin B. 2015 Sep;5(5):378-89. doi: 10.1016/j.apsb.2015.05.007. Epub 2015 Jun 06. PMID: 26579469; PMCID: PMC4629436.
Copy Download .nbib Format: NLM
Share it on

Acta Pharm Sin B. 2015 Sep;5(5):378-89. doi: 10.1016/j.apsb.2015.05.007. Epub 2015 Jun 06.

HIF-1α pathway: role, regulation and intervention for cancer therapy.

Acta pharmaceutica Sinica. B

Georgina N Masoud, Wei Li

Affiliations

  1. Department of Pharmaceutical Sciences, College of Pharmacy, the University of Tennessee Health Science Center, Memphis, TN 38163, USA.

PMID: 26579469 PMCID: PMC4629436 DOI: 10.1016/j.apsb.2015.05.007

Abstract

Hypoxia-inducible factor-1 (HIF-1) has been recognized as an important cancer drug target. Many recent studies have provided convincing evidences of strong correlation between elevated levels of HIF-1 and tumor metastasis, angiogenesis, poor patient prognosis as well as tumor resistance therapy. It was found that hypoxia (low O2 levels) is a common character in many types of solid tumors. As an adaptive response to hypoxic stress, hypoxic tumor cells activate several survival pathways to carry out their essential biological processes in different ways compared with normal cells. Recent advances in cancer biology at the cellular and molecular levels highlighted the HIF-1α pathway as a crucial survival pathway for which novel strategies of cancer therapy could be developed. However, targeting the HIF-1α pathway has been a challenging but promising progresses have been made in the past twenty years. This review summarizes the role and regulation of the HIF-1α in cancer, and recent therapeutic approaches targeting this important pathway.

Keywords: 4E-BP1, eukaryotic translation initiation factor 4E (eIF-4E) binding protein p70 S6 kinase (S6K); ADM, adrenomedullin; AKt, protein kinase B; ARD-1, arrest-defective-1; ARNT, aryl hydrocarbon nuclear translocator; AhR, aryl hydrocarbon receptor; C-MYC, myelocytomatosis virus oncogene cellular homolog; C-TAD, COOH-terminal TAD; CAC, circulating angiogenic cells; CPTs, camptothecins; Cancer drug discovery and development; ChIP, chromatin immunoprecipitation; CoCl2, cobalt chloride; DFO, deferoxamine; EGF, epidermal growth factor; ELISA, enzyme-linked immunosorbent assay; EMSA, electrophoretic mobility shift assay; EPO, erythropoietin; ERK, extracellular signal-regulated kinase; FIH-1, factor inhibiting HIF-1; GA, geldanamycin; GAs, geldanamycins; GLUT1, glucose transporter 1; GLUT3, glucose transporter 3; GLUTs, glucose transporters; HDAC, histone deacetylase; HIF-1α; HIF-1α inhibitors; HIF-1α, hypoxia-inducible factor-1α; HK1, hexokinase 1; HK2, hexokinase 2; HPH, HIF-1 prolyl hydroxylases; HRE, hypoxia response elements; HTS, high throughput screens; Hsp90, heat shock protein 90; ID2, DNA-binding protein inhibitor; IGF-BP2, IGF-factor-binding protein 2; IGF-BP3, IGF-factor-binding protein 3; IGF2, insulin-like growth factor 2; IPAS, inhibitory PAS; K, lysine residue; LDHA, lactate dehydrogenase; LEP, leptin; LRP1, LDL-receptor-related protein 1; Luc, luciferase; MAPK, mitogen-activated protein kinases; MEK, MAPK/ERK kinase; MNK, MAP kinase interacting kinase; MTs, microtubules; Mdm2, mouse double minute 2 homolog; N, asparagine residue; N-TAD, NH2-terminal TAD; NOS, nitric oxide synthase; ODDD, oxygen dependent degradation domain; P, proline residue; PAS, Per and Sim; PCAF, p300/CBP associated factor; PHDs, prolyl-4-hydroxylases; PI3K, phosphatidyl inositol-4,5-bisphosphate-3-kinase; PKM, pyruvate kinase M; RCC, renal cell carcinoma; RT-PCR, reverse transcription polymerase chain reaction; Raf, rapidly accelerated fibrosarcoma; Ras, rat sarcoma; SIRT 1, Sirtuin 1; TAD, transactivation domains; TGF-α, transforming growth factor α; TGF-β3, transforming growth factor beta3; TPT, topotecan; Top I, topoisomerase I; VEGF, vascular endothelial growth factor; bHLH, basic-helix-loop-helix; eIF-4E, eukaryotic translation initiation factor 4E; mTOR, mammalian target of rapamycin; pVHL, von Hippel-Lindau protein

References

  1. Cancer Control. 2003 Sep-Oct;10(5):361-9 - PubMed
  2. Nature. 1999 May 20;399(6733):271-5 - PubMed
  3. J Cell Mol Med. 2009 Sep;13(9A):2780-6 - PubMed
  4. Genes Dev. 2000 Aug 15;14(16):1983-91 - PubMed
  5. Proc Natl Acad Sci U S A. 1997 May 27;94(11):5667-72 - PubMed
  6. Cancer Res. 2005 Oct 1;65(19):9047-55 - PubMed
  7. J Biol Chem. 1985 Nov 25;260(27):14873-8 - PubMed
  8. Cancer Cell. 2003 Apr;3(4):363-75 - PubMed
  9. Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15351-6 - PubMed
  10. Cardiovasc Res. 2001 Feb 16;49(3):507-21 - PubMed
  11. Clin Cancer Res. 2008 Mar 15;14 (6):1888-96 - PubMed
  12. Mol Cancer Ther. 2008 Jun;7(6):1472-82 - PubMed
  13. Curr Opin Cell Biol. 2001 Apr;13(2):167-71 - PubMed
  14. Cancer Res. 2006 Jun 1;66(11):5549-54 - PubMed
  15. J Biol Chem. 2003 Apr 18;278(16):14013-9 - PubMed
  16. Mol Cell Biol. 2006 Mar;26(6):2019-28 - PubMed
  17. Lancet Oncol. 2008 Apr;9(4):342-51 - PubMed
  18. Science. 2001 Nov 9;294(5545):1337-40 - PubMed
  19. Mol Cancer Ther. 2004 May;3(5):647-54 - PubMed
  20. Biochem Pharmacol. 2010 Oct 1;80(7):982-9 - PubMed
  21. Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S61-75 - PubMed
  22. J Biol Chem. 1995 Jan 20;270(3):1230-7 - PubMed
  23. J Mol Med (Berl). 2012 Jan;90(1):45-54 - PubMed
  24. J Surg Res. 2011 May 15;167(2):173-81 - PubMed
  25. Jpn J Cancer Res. 2001 Dec;92 (12 ):1342-51 - PubMed
  26. Mol Cell Biol. 2002 Apr;22(8):2515-23 - PubMed
  27. Mol Cancer Ther. 2009 Jul;8(7):1867-77 - PubMed
  28. Cell Cycle. 2006 Aug;5(16):1847-53 - PubMed
  29. Cancer Res. 2002 Aug 1;62(15):4316-24 - PubMed
  30. Mol Cell Biol. 1996 Oct;16(10):5221-31 - PubMed
  31. FEBS Lett. 2004 Sep 24;575(1-3):59-63 - PubMed
  32. J Natl Cancer Inst. 2005 Sep 7;97(17 ):1272-86 - PubMed
  33. Proc Natl Acad Sci U S A. 2009 Feb 17;106(7):2353-8 - PubMed
  34. Blood. 1994 Dec 15;84(12):4226-33 - PubMed
  35. Cell Growth Differ. 2001 Jul;12 (7):363-9 - PubMed
  36. Mol Cell. 2010 Jun 25;38(6):864-78 - PubMed
  37. Science. 1988 Dec 9;242(4884):1412-5 - PubMed
  38. Cell. 2001 Oct 5;107(1):43-54 - PubMed
  39. Free Radic Biol Med. 2001 Oct 1;31(7):847-55 - PubMed
  40. Cancer Res. 2005 Jun 1;65(11):4918-28 - PubMed
  41. J Antibiot (Tokyo). 1994 Mar;47(3):301-10 - PubMed
  42. J Biol Chem. 1999 Nov 19;274(47):33709-13 - PubMed
  43. Methods Enzymol. 2007;435:385-402 - PubMed
  44. Nat Rev Cancer. 2003 Oct;3(10):721-32 - PubMed
  45. J Biol Chem. 2002 Jan 4;277(1):9-12 - PubMed
  46. Bull Cancer. 2010;97:45-51 - PubMed
  47. Biochem J. 2002 Nov 1;367(Pt 3):571-5 - PubMed
  48. J Biol Chem. 1996 Jul 26;271(30):17771-8 - PubMed
  49. Curr Top Med Chem. 2009;9(15):1386-418 - PubMed
  50. Mol Cell Biol. 2006 Aug;26(15):5895-907 - PubMed
  51. Eur J Med Chem. 2012 Mar;49:24-40 - PubMed
  52. Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):680s-684s - PubMed
  53. Gene. 2015 Apr 1;559(2):164-71 - PubMed
  54. Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5510-4 - PubMed
  55. Cell. 2002 Nov 27;111(5):709-20 - PubMed
  56. Mol Pharmacol. 2002 Nov;62(5):975-82 - PubMed
  57. Nat Rev Cancer. 2008 Sep;8(9):705-13 - PubMed
  58. Cancer Res. 2004 Feb 15;64(4):1475-82 - PubMed
  59. Cancer Cell. 2004 Jul;6(1):33-43 - PubMed
  60. Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4273-8 - PubMed
  61. Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12436-41 - PubMed
  62. BMC Cancer. 2007 Nov 13;7:213 - PubMed
  63. Cancer Res. 2002 Sep 1;62(17):4916-21 - PubMed
  64. Proc Natl Acad Sci U S A. 2009 Oct 20;106(42):17910-5 - PubMed
  65. Mol Cancer Ther. 2008 Jan;7(1):90-100 - PubMed
  66. Nature. 2001 Nov 29;414(6863):550-4 - PubMed
  67. J Biol Chem. 1997 Sep 5;272(36):22642-7 - PubMed
  68. Genes Dev. 2001 Apr 1;15(7):807-26 - PubMed
  69. Proc Natl Acad Sci U S A. 1991 Jul 1;88(13):5680-4 - PubMed
  70. J Biol Chem. 2002 Aug 16;277(33):29936-44 - PubMed
  71. J Biol Chem. 2001 Apr 20;276(16):12645-53 - PubMed
  72. Mol Cancer Ther. 2008 Nov;7(11):3598-608 - PubMed
  73. Biochem Pharmacol. 2001 Apr 15;61(8):947-54 - PubMed
  74. Genes Dev. 2002 Jun 15;16(12 ):1466-71 - PubMed
  75. Trends Mol Med. 2002;8(4 Suppl):S62-7 - PubMed
  76. Mol Pharmacol. 2006 Nov;70(5):1469-80 - PubMed
  77. Biochim Biophys Acta. 2005 Jul 25;1755(2):107-20 - PubMed
  78. Mol Cancer Ther. 2008 Dec;7(12 ):3729-38 - PubMed
  79. J Biol Chem. 1996 Aug 30;271(35):21262-7 - PubMed
  80. J Am Chem Soc. 2009 Dec 23;131(50):18078-88 - PubMed
  81. Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):19579-86 - PubMed
  82. Mol Oncol. 2015 Jan;9(1):309-22 - PubMed
  83. Biochem Pharmacol. 2002 Sep;64(5-6):993-8 - PubMed
  84. Pathol Biol (Paris). 2015 Feb;63(1):17-20 - PubMed
  85. Genes Dev. 2000 Jan 1;14(1):34-44 - PubMed

Publication Types

Grant support